The dose-response relationship demonstrates that higher doses produce greater reductions in HbA1c and body weight, with clinical effects sustained over long-term treatment (Davies et al., 2021)
Since last year, Medicare has covered the weight-loss formulations of GLP-1 products under its Part D (outpatient) drug program if beneficiaries had a separate Food and Drug Administration-approved indication
Having pre-portioned, healthy meals ready reduces decision fatigue when appetite is low
Mitochondrial miRNA determines chemoresistance by reprogramming metabolism and regulating mitochondrial transcription
The incidences of major depressive disorder, anxiety, and suicidal ideations or attempts, as well as their hazard ratios, are higher in the GLP-1 RA group, indicating an association with GLP-1 RA treatment over time
Explore sourcing options, quality considerations, and compliance for preclinical studies